Molecular structure of S-55746, CAS Number: 1448584-12-0
S-55746 (CAS 1448584-12-0)
CAS Number:
1448584-12-0
Molecular Weight:
710.831
Molecular Formula:
C43H42N4O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
S-55746 (CAS 1448584-12-0) References
- S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. | Casara, P., et al. 2018. Oncotarget. 9: 20075-20088. PMID: 29732004
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. | Moujalled, DM., et al. 2019. Leukemia. 33: 905-917. PMID: 30214012
- Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice. | Pierrillas, PB., et al. 2018. J Pharmacol Exp Ther. 367: 414-424. PMID: 30228112
- Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. | de Jong, Y., et al. 2018. Oncogenesis. 7: 74. PMID: 30242253
- Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy. | Pierrillas, PB., et al. 2019. Drug Metab Dispos. 47: 648-656. PMID: 30940629
- Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1. | Murray, JB., et al. 2019. ACS Omega. 4: 8892-8906. PMID: 31459977
- Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation. | Pierrillas, PB., et al. 2020. Invest New Drugs. 38: 1796-1806. PMID: 32451663
- Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. | Moujalled, DM., et al. 2020. Blood Adv. 4: 2762-2767. PMID: 32569380
- Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. | Thijssen, R., et al. 2021. Blood. 137: 2721-2735. PMID: 33824975
- Drug-repurposing against COVID-19 by targeting a key signaling pathway: An in silico study. | Oh, KK., et al. 2021. Med Hypotheses. 155: 110656. PMID: 34399157
Inhibitor of:
Bcl-2, BCLP, DNLC2A, and Mcl-1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
S-55746, 10 mg | sc-507289 | 10 mg | $750.00 |